S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Belmont Medical Technologies Acquires Software Firm Arcos

Belmont Medical Technologies has finalized the acquisition of Texas-based Arcos, Inc., a move designed to integrate advanced clinical software into its portfolio of fluid-resuscitation tools. The deal brings proprietary burn-care and blood-transfusion management systems under the Belmont umbrella, marking its third acquisition since partnering with Audax Private Equity in 2017.

Belmont Medical Technologies Acquires Software Firm Arcos
Photo: Bio & News

Founded in 2009 by Dr. George Kramer and Chris Meador, Arcos developed the Burn Navigator and BloodNav platforms to assist clinicians in high-stakes medical environments. BloodNav functions as a performance-improvement tool for Massive Transfusion Protocols, providing real-time data tracking and electronic medical record integration. By pairing this software with the Belmont Rapid Infuser, the company aims to streamline documentation and improve accuracy during emergency resuscitation procedures.

Burn Navigator, introduced in 2013, has become a standard support tool for managing adult and pediatric patients with severe burns. Belmont CEO Brian Larkin stated that the acquisition serves as a key milestone in the company’s growth strategy. For Arcos, the transition offers a path to scale its technology within broader trauma settings. The integration unites the Belmont Rapid Infuser’s hardware capabilities with the software-driven process oversight developed by the Arcos team.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!